INFASURF
(Calfactant)PreclinicalSmall molecule
INFASURF is one of 30 small molecule programs targeting Drug. It is currently in Preclinical.
1
Indications
6
Total Trials
2
Active Trials
29
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
34 competitors in Drug
#DrugCompanyPhaseTrials
1Nicorette
PfizerApproved
Inderal
WWyeth-Lederle Vaccines
Approved
Zyvox
PfizerPhase 3
Lamprene
NovartisPhase 3
Sirturo
WWim Janssens
Phase 3
Deltyba
OtsukaPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Ketalar
AAultman Health Foundation
Phase 3
T-Dxd
Daiichi SankyoPhase 3
Lenvima
EisaiPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Respiratory Distress Syndrome2 trials
Acute Lung Injury1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Jul 1, 1998
INFASURF
BLA BLA020521
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Calfactant. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- GGrit Biotechnology